Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Range-finding Study of Kiklin in CKD Patients on Hemodialysis
NCT02753894Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2008
- Primary completion
- Jun 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bixalomer in hyperphosphatemia (3 arms), sponsored by Astellas Pharma. Primary endpoint: Change from the baseline of serum phosphorus level at Week 6. Started Jan 2008; status: completed.
02
Drugs
bixalomer
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02753894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753894.